Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chimerigen
CD152 [CTLA-4] (mouse):Fc (mouse) (rec.) (non-lytic)
Product Details | |
---|---|
Synonyms | CTLA-4 |
Product Type | Protein |
Properties | |
Source/Host | NS1 cells |
Sequence |
The extracellular domain of mouse CD152 [CTLA-4] (aa 1-160) is fused to the N-terminus of the Fc region of a mutant mouse IgG2a. |
Crossreactivity | Mouse |
Biological Activity |
Blocks the binding of mouse CD80 (B7-1) and CD86 (B7-2) to their receptors (by binding CD80 and CD86 with high affinity) and thereby prevents their T cell regulatory actions by inhibiting the CD28 signaling competitively. Shows the biological functions of the CD152 moiety and exerts a prolonged circulating half-life caused by the modified Fc domain. Useful for investigating the T cell co-stimulation. |
Purity | ≥98% (SDS-PAGE) |
Endotoxin Content | <1EU/mg protein (LAL test; Lonza). |
Reconstitution | Reconstitute at 100μg/ml in sterile PBS. |
Formulation | Lyophilized from 0.2μm-filtered solution in PBS. |
Protein Negative Control | |
Other Product Data |
Non-lytic: Acts as a long lasting fusion protein which only binds to the receptor. Mutations to the complement (C1q) and FcgR I binding sites of the IgGs Fc fragment render the fusion proteins incapable of antibody directed cytotoxicity (ADCC) and complement directed cytotoxicity (CDC). |
Declaration | Manufactured by Chimerigen. |
Shipping and Handling | |
Shipping | BLUE ICE |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice |
Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. |
Use/Stability |
Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
CD152 [CTLA-4] and CD28, together with their ligands B7-1 and B7-2, constitute one of the dominant costimulatory pathways that regulate T and B cell responses. CD152 and CD28 are structurally homologous molecules that are members of the immunoglobulin (Ig) gene superfamily. Both CD152 and CD28 are composed of a single Ig V-like extracellular domain, a transmembrane domain and an intracellular domain. CD152 and CD28 are both expressed on the cell surface as disulfide-linked homodimers or as monomers. CD152 was originally identified as a gene that was specifically expressed by cytotoxic T lymphocytes. However, CD152 transcripts have since been found in both Th1 and Th2, and CD4+ and CD8+ T cell clones. Whereas, CD28 expression is constitutive on the surfaces of 95% of CD4+ T cells and 50% of CD8+ T cells and is down regulated upon T cell activation, CD152 expression is upregulated rapidly following T cell activation and peaks approximately 24 hours following activation. Although both CD152 and CD28 can bind to the same ligands, CD152 binds to B71 and B72 with 20-100-fold higher affinity than CD28.
- Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance: W. Steurer, et al.; J. Immunol. 155, 1165 (1995)
- CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice : E.A. Tivol, et al.; J. Immunol. 158, 5091 (1997)
- Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation: J.A. Gonzalo, et al.; J. Immunol. 166, 1 (2001)
- Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease: S. Paust, et al.; PNAS 101, 10398 (2004)
- Embryonic Pig Pancreatic Tissue Transplantation for the Treatment of Diabetes: S. Eventov-Friedman, et al.; PLoS Med. 3, e215 (2006)
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses: M.J. Butte, et al.; Immunity 27, 111 (2007)
- Pig Embryonic Pancreatic Tissue as a Source for Transplantation in Diabetes: D. Tchorsh-Yutsis, et al.; Diabetes 58, 1585 (2009)
- Selective CD28 Blockade Attenuates Acute and Chronic Rejection of Murine Cardiac Allografts in a CTLA-4-Dependent Manner: T. Zhang, et al.; Am. J. Transplant. 11, 1599 (2011)